This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Hologic (HOLX) Gains From Core Businesses' Growth, Innovation
by Zacks Equity Research
Hologic's (HOLX) GYN Surgical business grows organically as the company registers procedural volumes return and acceleration from new business lines.
Surmodics' (SRDX) Receipt of New FDA Nod to Boost Patient Care
by Zacks Equity Research
Surmodics' (SRDX) receipt of FDA's clearance is expected to expand the treatment range of the Pounce platform and serve a wider patient pool.
Is Augmedix (AUGX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Augmedix, Inc. (AUGX) and Boston Scientific (BSX) have performed compared to their sector so far this year.
IDEXX (IDXX) Launches First Veterinary Diagnostic Test
by Zacks Equity Research
IDEXX's (IDXX) Cystatin B Test can help veterinary professionals to spot kidney damage before it affects kidney function, which may result in better patient outcomes.
3 Reasons to Hold Patterson Companies (PDCO) Stock for Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
BD's (BDX) Latest Product to Automate Clinical Flow Cytometry
by Zacks Equity Research
The latest worldwide commercial availability of BD's (BDX) product is expected to lead to increased automation in clinical lab workflow.
Neogen (NEOG) Introduces Improved Genomic Test for Cats
by Zacks Equity Research
Neogen's (NEOG) My CatScan 2.0 offers insightful genetic information that enables preventive cat care by tackling curable conditions.
Here's Why You Should Invest in Hologic (HOLX) Stock Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX) on continued strength in GYN Surgical and Breast Health businesses.
Centene (CNC) Divests Apixio to Boost Its Core Business
by Zacks Equity Research
Centene (CNC) completes the sale of Apixio to New Mountain Capital in a bid to dispose of non-core assets and grow its core Managed Care business.
QIAGEN's (QGEN) QCI Is Used by Danish National Genome Center
by Zacks Equity Research
QIAGEN's (QGEN) QCI Interpret offers evidence-based variant interpretation and reporting, and upholds the highest standards for data security and privacy. It also provides testing sites flexibility.
Here's Why You Should Retain Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Illumina (ILMN) on solid long-term growth potential in the oncology space.
CVS Heath (CVS) MinuteClinic Earns 6th Health Care Approval
by Zacks Equity Research
CVS Heath's (CVS) MinuteClinic has an in-clinic Net Promotor Score of more than 81, putting it in the top customer rankings.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and product launches.
Catalent (CTLT) Tops Q3 Earnings Estimates, Cuts FY23 View
by Zacks Equity Research
Catalent (CTLT) records lower revenues in both segments in third-quarter fiscal 2023, resulting in overall soft performance.
Teleflex's (TFX) Arrow EZ-IO Needle Receives FDA Approval
by Zacks Equity Research
Teleflex's (TFX) Arrow EZ-IO Needle is the first and only intraosseous (IO) needle for MR Conditional labelling.
Catalent (CTLT) Launches Expanded OneBio Suite to Aid Customers
by Zacks Equity Research
Catalent's (CTLT) expansion of its OneBio Suite across multiple biologic therapies is expected to aid customers in leveraging its end-to-end capabilities in these areas.
Inari Medical (NARI) Launches New Catheters to Address VTE
by Zacks Equity Research
Inari Medical's (NARI) latest launches are expected to serve a wider patient pool by improving treatment options.
3 Reasons to Retain Intuitive Surgical (ISRG) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Intuitive Surgical (ISRG) owing to its strength in robotics.
Masimo's (MASI) New FDA Approval to Boost Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) Radius VSM is expected to equip any hospital bed with comprehensive monitoring and offer more personalized care without additional bedside equipment.
HealthEquity (HQY) Surpasses Q1 Earnings Estimates, FY24 View Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2024.
Here's Why You Should Hold Integer Holdings (ITGR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and a solid foothold in the broader MedTech space.
Hologic (HOLX) Stock Up 5.6% YTD: Will the Rally Continue?
by Zacks Equity Research
The higher capital equipment revenues, procedural volumes return and an acceleration from the new business lines poise Hologic (HOLX) for future growth.
Here's Why You Should Hold on to Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) owing to expanding work-flow options of its leading iTero scanners.
Here's Why You Should Retain AMN Healthcare (AMN) Stock for Now
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
Here's Why You Should Retain PacBio (PACB) Stock for Now
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.